Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of 99mTc-hydrazinonicotinamide-PEG4-E[PEG4-c(RGDfk)]2 (99mTc-3PRGD2) SPECT/CT for Integrin αVβ3 Imaging of Lung Cancer and Mapping Lymph Node Metastases: A Prospective Multicenter, Self-controlled, Phase 3 Trial

NCT04233476 is registered in ClinicalTrials.gov with RDO Pharm. as lead sponsor.

NCT NCT04233476
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04233476 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of 99mTc-hydrazinonicotinamide-PEG4-E[PEG4-c(RGDfk)]2 (99mTc-3PRGD2) SPECT/CT for Integrin αVβ3 Imaging of Lung Cancer and Mapping Lymph Node Metastases: A Prospective Multicenter, Self-controlled, Phase 3 Trial
Lead sponsor
RDO Pharm.
Phase
Phase 3
Overall status
Completed
Start date
October 12, 2019
Completion date
May 8, 2021
Enrollment
409 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, lymph node metastasis